The Biomolecules and Biomedicine is an international, peer-reviewed journal. Journal IF 2024: 2.2 Broad readership and scope. Open Access. Editorial Board.
The Biomolecules and Biomedicine (formerly, the Bosnian Journal of Basic Medical Sciences, BJBMS) is а premier venue for preclinical and clinical biomedical science discoveries. The journal was founded in 1998 and is published by the Association of Basic Medical Sciences, a nonprofit honor organization of physician-scientists. The Biomolecules and Biomedicine reaches readers across a wide range of
medical disciplines and sectors. The Journal publishes basic and translational/clinical research submissions and reviews in all biomedical specialties, including Genetics and Molecular biology, Immunology, Microbiology, Pathology, Biochemistry, Pharmacology, Anatomy, Biomaterials, New and Emerging Research and Diagnostic Methods, New and Emerging Medical Entities, and others. All research is available to the public for free. The Biomolecules and Biomedicine deposits published articles in PubMed Central, satisfying the NIH Public Access Policy and other similar funding agency requirements. Renowned international experts in the Journal's Editorial Board, together with external peer-reviewers, select the best submissions for publication. High visibility
Open Access: articles are freely available to readers immediately after publication. Highly accessed online content: more than 350,000 readers/month (100,000 at PubMed Central (April 2024); 120,000 at Journal's website (April 2024); more than 130,000 at Web of Science, Scopus, Google Scholar, and others). Newsletters: more than 20,000 registered users receive a newsletter tailored to their field of interest. Social media: articles are promoted through various social media channels (Twitter, LinkedIn, Facebook)
Advance online: all accepted articles are published Advance online and Ahead of print on PubMed within 3 days of acceptance, with citable DOIs, to make the article accessible as fast as possible. Print circulation: 200 copies of print issues are sent to major libraries, institutes, universities, conferences, and subscribers worldwide. BiomolBiomed Viewpoints: Journal's blog promotes authors and their research by publishing plain language summaries for a broad audience and media, as well as commentaries, interviews, news, and stories related to science and research. Indexing and abstracting
SCIE (Science Citation Index Expanded), Web of Science, Clarivate Analytics
JCR (Journal Citation Reports®), Clarivate Analytics
PubMed/MEDLINE (Biomol Biomed)
PubMed/MEDLINE (BJBMS)
PubMed Central (PMC)
SCOPUS
SJR (Scimago Journal and Country Rank) (BiomolBiomed)
SJR (Scimago Journal and Country Rank) (BJBMS)
DOAJ
SCILIT (BiomolBiomed)
SCILIT (BJBMS)
EBSCO
PROQUEST
Dimensions
Semantic Scholar
Google Scholar
EMBASE/Excerpta Medica
Europe PubMed Central
Medscape
ISSN Portal
ROAD
HINARI
CAS
X-MOL
CNKI
many libraries
Timely publication
The 2023 peer review performance metrics:
Number of submissions (2023): 1288
Average time from submission to initial decision (reject or peer review): 2 days
Average peer-review time and decision: 22 days
Average time from acceptance to advance online publication: 2 days
Average number of reviews received per manuscript: 4
Acceptance Rate: 15%
Meaningful metrics
The success of the articles published in BiomolBiomed is tracked in real-time by individualized Article-Level Metrics (Dimensions and PlumX). These reflect the viewership, download rates, social sharing, citations, field citation ratio, and relative citation ratio for each published article in real-time, and help you illustrate the impact of your research
Small cell lung cancer (SCLC): At the door of targeted therapies
After decades of limited progress and near-universal relapse, DLL3- and B7-H3–directed strategies are showing clinically meaningful activity in extensive-stage SCLC—highlighting tarlatamab’s survival advantage and strong late-line responses with I-DXd. The next research question is no longer whether targets exist, but how to sequence and combine these agents, manage BiTE-specific toxicities (CRS/ICANS), and develop biomarkers that can reliably guide patient selection across SCLC subtypes.
In a standardized rat dorsal skin flap model, continuous topical nitroglycerin was associated with a marked increase in pedicle-independent viable area after day-5 pedicle division (≈84% vs ≈30% in controls; P
Topical Nitroglycerin Improves Skin Flap Survival by Boosting Blood Vessel Growth; continuous dosing raised pedicle-independent viability in rats.
17/12/2025
TUBB, CLTA, and FBXL5 as Blood Markers for Postmenopausal Osteoporosis
By moving the focus from bone tissue to peripheral blood, this research offers a different perspective on osteoporosis biology. The findings raise important questions about immune regulation, RNA modification, and their relevance to disease heterogeneity.
Identifies TUBB CLTA and FBXL5 as Blood Markers for Postmenopausal Osteoporosis, using peripheral blood gene expression analysis.
15/12/2025
Extraovarian fibrothecoma: a benign tumor that can mimic ovarian cancer
Elevated CA-125, ascites, and postmenopausal pelvic masses usually trigger an oncologic alarm—but what if the diagnosis is benign? This rare extraovarian entity highlights critical diagnostic pitfalls and underscores the importance of careful morphologic and immunohistochemical evaluation to avoid overtreatment.
Extraovarian fibrothecoma: a benign tumor that can mimic ovarian cancer, often presenting with ascites and elevated CA-125.
12/12/2025
How Tumors Rewire Glucose Metabolism to Escape Copper-Induced Cell Death
A recent review outlines how aerobic glycolysis, PPP-driven NADPH/GSH, and PDK-mediated PDH inhibition can jointly suppress cuproptosis by limiting lipoylated mitochondrial targets and buffering copper stress. If your work touches tumor metabolism or metal biology, the proposed combination strategies—reactivating TCA flux while constraining NADPH/GSH and pairing with copper ionophores—are worth a closer look.
How Tumors Rewire Glucose Metabolism to Escape Copper-Induced Cell Death: review links glycolysis/PPP, NADPH-GSH and PDKs to cuproptosis resistance.
10/12/2025
Presepsin shows strong potential for improving sepsis diagnosis
A review of 47 studies brings new clarity to presepsin’s role in detecting sepsis earlier and more reliably. Researchers may find the age-specific performance and methodological comparisons particularly impactful for future diagnostic strategies.
Presepsin Shows Strong Potential for Improving Sepsis Diagnosis by supporting faster, reliable detection and helping identify sepsis earlier.
10/12/2025
The Reviewer of the Month for December 2025: Marko Bojović, MD
Peer review is fundamental to ensuring the rigor and reliability of scientific publishing. This month, Biomolecules and Biomedicine proudly highlights Dr. Marko Bojović as our Reviewer of the Month for December 2025.
Dr. Bojović is a Radiation Oncologist at the Oncology Institute of Vojvodina and an Assistant at the University of Novi Sad. His research covers a wide range of oncology topics—including optimized radiotherapy schedules, diagnostic approaches in lung cancer, and long-term studies of ultrahypofractionated radiotherapy.
His reviews are consistently comprehensive, constructive, and grounded in deep clinical expertise. We are grateful for his commitment to maintaining high standards in peer review and supporting ongoing scientific progress.
The Reviewer of the Month for December 2025: Marko Bojović, MD, recognized for excellence in peer review and advancing scientific publishing quality.
08/12/2025
Sugammadex vs. Neostigmine: New Evidence on Post-Anesthesia Recovery
What if the drugs used at the end of surgery could change a patient’s immediate safety and comfort just as much as the anesthesia itself? A new analysis shows surprising differences in how two commonly used reversal agents shape recovery, and why those differences matter more than most people realise.
Read more below:
Author summary: (FIND LINK IN BIO).
08/12/2025
Sugammadex vs. Neostigmine: New Evidence on Post-Anesthesia Recovery
What if the drugs used at the end of surgery could change a patient’s immediate safety and comfort just as much as the anesthesia itself? A new analysis shows surprising differences in how two commonly used reversal agents shape recovery, and why those differences matter more than most people realise.
Sugammadex vs. Neostigmine: New Evidence on Post-Anesthesia Recovery highlights risks of residual blockade and compares two strategies for safer outcomes.
05/12/2025
How Gut Microbial Metabolites Impact Alzheimer's Disease: Insights into the Brain-Gut Axis
Recent research reveals the gut microbiota's critical role in Alzheimer’s disease, challenging traditional views and offering new avenues for treatment. Explore how microbial metabolites, such as short-chain fatty acids and TMAO, could become key targets for Alzheimer’s therapies.
Learn how gut microbial metabolites impact Alzheimer's disease through the brain-gut axis, offering new insights into disease progression and treatment.
03/12/2025
The new issue of Biomolecules and Biomedicine (Vol. 25, No. 12) is now live!
This edition brings together high-impact studies across AI-powered imaging, oncology, neurology, metabolic disease, pediatrics, and maternal–fetal medicine—designed to support researchers and clinicians at the forefront of biomedical science.
Highlights from this issue include:
• AI-driven CT body composition analysis that challenges the limits of BMI for individualized risk assessment
• Emerging immunotherapy biomarkers in cervical cancer and colorectal cancer
• Meta-analyses linking frailty to survival in RCC and weight variability to dementia risk
• First-trimester tools that strengthen early detection of preeclampsia
• New insights across oncology, neurology, diabetes, liver disease, inflammatory markers, and more
For researchers. For clinicians. For curious readers.
Read a full issue online here: (FIND LINK IN BIO)
03/12/2025
The new issue of Biomolecules and Biomedicine (Vol. 25, No. 12) is now live!
This edition brings together high-impact studies across AI-powered imaging, oncology, neurology, metabolic disease, pediatrics, and maternal–fetal medicine—designed to support researchers and clinicians at the forefront of biomedical science.
Highlights from this issue include:
• AI-driven CT body composition analysis that challenges the limits of BMI for individualized risk assessment
• Emerging immunotherapy biomarkers in cervical cancer and colorectal cancer
• Meta-analyses linking frailty to survival in RCC and weight variability to dementia risk
• First-trimester tools that strengthen early detection of preeclampsia
• New insights across oncology, neurology, diabetes, liver disease, inflammatory markers, and more
For researchers. For clinicians. For curious readers.
The Biomolecules and Biomedicine is a premier open-access biomedical journal covering a wide range of preclinical, translational and clinical research.
Be the first to know and let us send you an email when Biomolecules and Biomedicine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
The BJBMS (Bosnian Journal of Basic Medical Sciences) is а premier venue for discoveries in basic and clinical biomedical science. The BJBMS was founded in 1998 and is published by the Association of Basic Medical Sciences, a nonprofit honor organization of physician-scientists.
Broad readership and scope. The BJBMS reaches readers across a wide range of medical disciplines and sectors. The journal publishes basic and translational/clinical research submissions and reviews in all biomedical specialties, including Genetics and Molecular biology, Immunology, Microbiology, Pathology, Biochemistry, Pharmacology, Anatomy, Biomaterials, new and emerging research and diagnostic methods, new and emerging medical entities, and others.
Open access. All research is available to the public for free. The BJBMS deposits published articles in PubMed Central, which satisfies the NIH Public Access Policy and other similar funding agency requirements.
Editorial Board. Renowned international experts in the journal's Editorial Board, together with external peer-reviewers select the best of the submissions for publication.
High visibility
Open Access: articles are freely available to readers immediately after publication.
Highly accessed online content: more than 150,000 visits/month (45,000 at PubMed Central (October 2019); 50,000 at Journal's website (March 2020); 45,000 at Web of Science, Scopus, Google Scholar, and others).
Newsletters: more than 9,000 registered users receive a newsletter tailored to their field of interest.
Social media: articles are promoted through various social media channels (Twitter, LinkedIn, Facebook)
Advanced online: all accepted articles are published Advanced online and Ahead of print on PubMed within 3 days of acceptance, with citable DOIs, to make the article accessible as fast as possible.
Print circulation: 300 copies of print issues are sent to major libraries, institutes, universities, conferences, and subscribers across the globe. Get the free sample copy here.
BJBMS Viewpoints: Journal's blog that promotes authors and their research by publishing plain language summaries for wide audience and media, as well as commentaries, interviews, news and stories related to science and research.
Indexing and abstracting
Science Citation Index Expanded (Web of Science, Clarivate Analytics)
Journal Citation Reports® (JCR)
PubMed/MEDLINE
PubMed Central (PMC)
SCOPUS
DOAJ
EBSCO
PROQUEST
Dimensions
Semantic Scholar
Google Scholar
EMBASE/Excerpta Medica
Europe PubMed Central
Medscape
ROAD
HINARI
CAS
many libraries
Timely publication
Time to First Editorial Decision (Rejection or Peer Review): 3 days
Time to First Decision after review (Rejection or Revision or Acceptance): 25 days
Time from Acceptance to Publication: 3 days (if no significant language editing is required)
Rejections without peer review: 40%
Acceptance Rate: 15%
Meaningful metrics
The success of the articles published in BJBMS is tracked in real-time by individualized Article-Level Metrics (Dimensions and PlumX). These reflect the viewership, download rates, social sharing, citations, field citation ratio, and relative citation ratio for each published article in a real-time, and help you illustrate the impact of your research
